Paratek amends bylaws to comply with SEC universal proxy rules and DGCL updates

Paratek Pharmaceuticals, Inc.

Board approved Amended and Restated Bylaws effective March 9, 2023.
Bylaws update procedural requirements for stockholder director nominations under SEC universal proxy rules.
Removes requirement to produce a stockholder list at meetings; adds Rule 14a-19 compliance mandate.
Prohibits additional or substitute nominations after the deadline and requires stockholder appearance at meetings.
Reserves white proxy cards for company use; other solicitors must use a different color.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Paratek Pharmaceuticals, Inc.: Amended and restated bylaws to update procedural requirements for director nominations and other administrative changes, effective March 9, 2023 (effective 2023-03-09).

Change: bylaw amendment
Effective: 2023-03-09

Exact text from the filing

On March 9, 2023 the Board of Directors (the “Board”) of Paratek Pharmaceuticals, Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”), effective as of such date.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001628280-23-007771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.